^
Association details:
| Biomarker: | KMT2C mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer
Published date:
01/05/2023
Excerpt:
Patients with KMT2C/D LOF benefited from ICIs in colorectal cancer in the MSKCC cohort….Overall, seven patients achieved partial response (PR), 14 patients achieved stable disease (SD), and seven patients achieved progressive disease (PD), resulting in an ORR rate of 25% (7/28). Among the 28 patients, 4 patients had KMT2C/D LOF mutations.
DOI:
https://doi.org/10.1111/cas.15716
Source:
Title:
The predictive values of loss-of-function variants in histone methyltransferases for response to immune checkpoint inhibitors in solid tumors.
Published date:
05/19/2021
Excerpt:
...we explored the associations of LOF variants in some HMTs with TMB and benefit from immune checkpoint inhibitors (ICIs) in solid tumors….KMT2C LOF variants were significantly correlated with longer median OS in colorectal cancer (P = 0.0171), but not in other cancer types.
DOI:
10.1200/JCO.2021.39.15_suppl.2586
Source:
Title:
Association of KMT2C/D loss-of-function mutations with tumor infiltrating lymphocytes and response to immune checkpoint inhibitors in solid tumors.
Published date:
05/19/2021
Excerpt:
...we explored the associations of KMT2C/D loss-of-function (LOF) mutations with the expression of immune-related genes, the levels of tumor infiltrating lymphocytes (TILs), and response to immune checkpoint inhibitors (ICIs)….The results showed that the predictive role of KMT2C/D LOF mutations for the clinical efficacy of ICIs therapy was only observed in colorectal cancer (P = 0.045).
DOI:
10.1200/JCO.2021.39.15_suppl.2587
Source:
Title:
Association of KMT2C mutations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.
Published date:
05/19/2021
Excerpt:
A multivariable analysis across the pan-cancer cohort using Cox proportional-hazards regression demonstrated that KMT2C mutation was significantly associated with better OS (hazard ratio, 0.69; 95%CI, 0.52-0.90; P = 0.006), and association remained significant with bladder (P = 0.039), colorectal (P = 0.024), melanoma (P < 0.001) and renal (P < 0.001)...
DOI:
10.1200/JCO.2021.39.15_suppl.2600
Source:
Title:
1639 - Correlation of KMT2C/D loss-of-function mutations with PD-L1 expression and response to immune checkpoint inhibitors in solid tumors
Published date:
03/10/2021
Excerpt:
We classified the patients into two groups: KMT2C/D LOF (any truncating mutation) and non-LOF…. In MSKCC cohort, colorectal cancer patients in the LOF group had significantly longer median overall survival (OS) after ICIs therapy (34 vs 13 months, P = 0.0485)....Furthermore, KMT2C/D LOF mutations were also associated with better response to ICIs in colorectal cancer and NSCLC...
Source:
Title:
497P Investigating the potential relationship between KMT2C/KMT2D mutations and immune checkpoint inhibitor (ICI) in colorectal cancer (CRC)
Published date:
09/01/2020
Excerpt:
...the median OS differed widely (34 vs. 13 months) in KMT2C/2D MT and WT group (HR 0.46, 95% CI 0.24 to 0.88, p<0.05) ; the results supported that mutations in KMT2C/2D was associated with higher TMB and OS with ICI treatment.
DOI:
10.1016/j.annonc.2020.08.607
